FBP1: A Potential Drug Target and Biomarker (G2203)

Target Name: FBP1

NCBI ID: G2203

FBP1

FBP1: A Potential Drug Target and Biomarker

Fructose-biphosphatase (FBPase) is an enzyme that plays a crucial role in the metabolism of fructose, which is a type of sugar found in fruits, vegetables, and some dairy products. FBPase catalyzes the conversion of fructose-6-phosphate (F6P) to fructose-1,6-bisfosphate (F1,6BP), which is then used to synthesize glucose-6-phosphate (G6P) and other carbonate compounds. The regulation of FBPase activity is critical for the proper functioning of many cellular processes, including cell growth, metabolism, and inflammation.

Given its importance in cellular metabolism, it is not surprising that FBPase has been identified as a potential drug target. Many diseases, including diabetes, cardiovascular disease, and cancer, are caused by disruptions in the normal function of cellular metabolism. By targeting FBPase, researchers hope to develop new treatments for these diseases.

FBPase has also been identified as a biomarker for several diseases, including diabetes, cancer, and cardiovascular disease. The levels of FBPase activity in these diseases often differ significantly from the levels in healthy cells. For example, individuals with type 2 diabetes tend to have lower FBPase activity than those without the disease. Similarly, individuals with cancer may have increased FBPase activity due to the increased metabolism that occurs in cancer cells.

In addition to its potential as a drug target and biomarker, FBPase also has important structural and functional roles in various cellular processes. The structure of FBPase is highly conserved across different species, which suggests that it has a critical role in the basic metabolism of fructose. FBPase is a member of the superfamily of enzymes known as the hexokinases, which include enzymes involved in the metabolism of various carbon compounds.

FBPase activity can also be regulated by various chemical inhibitors, such as inhibitors of phosphorylating enzymes or inhibitors of theATPaseKa, which is a subunit of FBPase. These inhibitors can either activate or inhibit FBPase activity depending on the specific context. The use of inhibitors of FBPase activity may be a promising strategy for the development of new treatments for diseases caused by disruptions in cellular metabolism.

In conclusion, FBPase is a critical enzyme involved in the metabolism of fructose. Its regulation is critical for the proper functioning of many cellular processes, including cell growth, metabolism, and inflammation. The identification of FBPase as a potential drug target and biomarker suggests that researchers may be on the path to developing new treatments for a variety of diseases. Further research is needed to fully understand the role of FBPase in cellular metabolism and to develop effective treatments based on this knowledge.

Protein Name: Fructose-bisphosphatase 1

Functions: Catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate in the presence of divalent cations, acting as a rate-limiting enzyme in gluconeogenesis. Plays a role in regulating glucose sensing and insulin secretion of pancreatic beta-cells. Appears to modulate glycerol gluconeogenesis in liver. Important regulator of appetite and adiposity; increased expression of the protein in liver after nutrient excess increases circulating satiety hormones and reduces appetite-stimulating neuropeptides and thus seems to provide a feedback mechanism to limit weight gain

The "FBP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets